Physician profile
Rajiv J Patel
NPI 1134311756
$32,944.75
in general payments reported to CMS, 2019-2025
32 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,568 · 2021: $4,705 · 2022: $4,717 · 2023: $5,026 · 2024: $1,715 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,907 · Travel and Lodging: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,907.12 |
| Travel and Lodging | $2,382.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23,723.61 | 2019-2025 | Watchman Access System, Resonate El Icd Vr, Accolade Sr |
| Abbott Laboratories | $3,622.78 | 2019-2025 | Amplatzer Amulet, Aveir |
| Abiomed | $1,467.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $524.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $512.26 | 2019-2025 | Wainua, Farxiga |
| Amgen INC. | $469.55 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.78 | 2019-2025 | Jardiance |
| Pfizer INC. | $299.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $262.96 | 2019-2024 | Xarelto |
| Heartflow, INC. | $226.24 | 2023-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $182.64 | 2019 | |
| Medtronic, INC. | $169.68 | 2024-2025 | Corevalve Evolut R, Symplicity G3 |
| Merck Sharp & Dohme LLC | $165.62 | 2022-2025 | Verquvo |
| Cvrx, INC. | $160.29 | 2020-2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $146.12 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $136.45 | 2023-2024 | Wegovy |
| Arbor Pharmaceuticals, INC. | $109.67 | 2019-2021 | |
| Baxter Healthcare | $71.72 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Azurity Pharmaceuticals, INC. | $69.05 | 2023-2024 | Edarbi, Edarbi |
| E.R. Squibb & Sons, L.L.C. | $67.81 | 2021-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $44.24 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $30.35 | 2024 | Arcalyst |
| Philips North America LLC | $26.74 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Lantheus Medical Imaging, INC. | $23.03 | 2024 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Lilly USA, LLC | $19.21 | 2025 | Mounjaro, Zepbound |
| Medtronic Vascular, INC. | $17.77 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.25 | 2023 | Arcalyst |
| Ani Pharmaceuticals, INC. | $15.79 | 2024 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $15.00 | 2019 | |
| Glaxosmithkline, LLC. | $13.47 | 2025 | Arexvy, Shingrix |
| Amryt Pharma Holdings Ltd | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.